Subscriber Authentication Point
lvrea
Home All issues Volume 27 / No 4 (Juillet 2018) Méd. Intensive Réa., 27 4 (2018) 324-330 References
Free Access
Issue
Méd. Intensive Réa.
Volume 27, Number 4, Juillet 2018
Médecine interne et transversalité
Page(s) 324 - 330
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0059
Published online 15 July 2018
  • Nimmerjahn F, Ravetch JV, (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513–533. doi: 10.1146/annurev.immunol.26.021607.090232 [CrossRef] [PubMed] [Google Scholar]
  • Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP, (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228–1231 [CrossRef] [PubMed] [Google Scholar]
  • Looney RJ, Huggins J, (2006) Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 19: 3–25. doi: 10.1016/j.beha.2005.01.032 [CrossRef] [PubMed] [Google Scholar]
  • Kazatchkine MD, Kaveri SV, (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747–755. doi: 10.1056/NEJMra993360 [CrossRef] [PubMed] [Google Scholar]
  • Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R, (2009) Intravenous immunoglobulins — understanding properties and mechanisms. Clin Exp Immunol 158: 2–13. doi: 10.1111/j.1365-2249.2009.04022.x [CrossRef] [Google Scholar]
  • Durandy A, Wahn V, Petteway S, Gelfand EW, (2005) Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success. Int Arch Allergy Immunol 136: 217–229. doi: 10.1159/000083948 [CrossRef] [PubMed] [Google Scholar]
  • Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B, (1996) Prophylaxis against infections with low-dose intravenous immunoglobulins, (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81: 121–126 [Google Scholar]
  • Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Clift RA, Hansen JA, Sanders JE, Thomas ED, Storb , (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323: 705–712. doi: 10.1056/NEJM199009133231103 [CrossRef] [PubMed] [Google Scholar]
  • Schwab I, Nimmerjahn F, (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13: 176–189. doi: 10.1038/nri3401 [CrossRef] [PubMed] [Google Scholar]
  • Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO, (2007) Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 1110: 426–432. doi: 10.1196/annals.1423.044 [CrossRef] [PubMed] [Google Scholar]
  • Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV, (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161: 3781–3790 [PubMed] [Google Scholar]
  • Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE, (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282: 490–493 [CrossRef] [Google Scholar]
  • Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C, (1993) Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342: 945–949 [CrossRef] [PubMed] [Google Scholar]
  • Samuelsson A, Towers TL, Ravetch JV, (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484–486. doi: 10.1126/science.291.5503.484 [CrossRef] [Google Scholar]
  • Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lünemann JD, (2009) Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 106: 4788–4792. doi: 10.1073/pnas.0807319106 [CrossRef] [PubMed] [Google Scholar]
  • Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N, (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 715–722. doi: 10.1182/blood-2007-03-079947 [CrossRef] [Google Scholar]
  • Séïté JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S, (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116: 1698–1704. doi: 10.1182/blood-2009-12-261461 [CrossRef] [Google Scholar]
  • Kaneko Y, Nimmerjahn F, Ravetch JV, (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670–673. doi: 10.1126/science.1129594 [CrossRef] [Google Scholar]
  • Schwab I, Biburger M, Krönke G, Schett G, Nimmerjahn F, (2012) IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 42: 826–830. doi: 10.1002/eji.201142260 [CrossRef] [PubMed] [Google Scholar]
  • Burks AW, Sampson HA, Buckley RH, (1986) Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314: 560–564. doi: 10.1056/NEJM198602273140907 [Google Scholar]
  • Welles CC, Tambra S, Lafayette RA, (2010) Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 55: 148–151. doi: 10.1053/j.ajkd.2009.06.013 [CrossRef] [PubMed] [Google Scholar]
  • Matsuda M, Hosoda W, Sekijima Y, Hoshi K, Hashimoto T, Itoh S, Ikeda S, (2003) Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 26: 306–311 [CrossRef] [PubMed] [Google Scholar]
  • Reinhart WH, Berchtold PE, (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339: 662–664 [CrossRef] [PubMed] [Google Scholar]
  • Go RS, Call TG, (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc Mayo Clin 75: 83–85. doi: 10.4065/75.1.83 [CrossRef] [Google Scholar]
  • Katz KA, Hivnor CM, Geist DE, Shapiro M, Ming ME, Werth VP, (2003) Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 139: 991–993. doi: 10.1001/archderm.139.8.991 [CrossRef] [PubMed] [Google Scholar]
  • Dickenmann M, Oettl T, Mihatsch MJ, (2008) Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 51: 491–503. doi: 10.1053/j.ajkd.2007.10.044 [CrossRef] [PubMed] [Google Scholar]
  • Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ, (1987) Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 82: 624–629 [CrossRef] [Google Scholar]
  • Ruggeri M, Castaman G, De Nardi G, Rodeghiero F, (1993) Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. Haematologica 78: 338–339 [PubMed] [Google Scholar]
  • Cayco AV, Perazella MA, Hayslett JP, (1997) Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 8: 1788–1794 [Google Scholar]
  • Decocq G, de Cagny B, Andréjak M, Desablens B, (1996) Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature. Therapie 51: 516–526 [PubMed] [Google Scholar]
  • Arunabh S, Kumar G, Avila V, (1996) Acute renal failure induced by intravenous immune globulin. Am Fam Physician 53: 862–865 [PubMed] [Google Scholar]
  • Ahsan N, Wiegand LA, Abendroth CS, Manning EC, (1996) Acute renal failure following immunoglobulin therapy. Am J Nephrol 16: 532–536 [CrossRef] [PubMed] [Google Scholar]
  • Sati HI, Ahya R, Watson HG, (2001) Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 113: 556–557 [CrossRef] [PubMed] [Google Scholar]
  • Fakhouri F, (2007) Intravenous immunoglobulins and acute renal failure: mechanism and prevention. Rev Med Interne 28: 4–6 [PubMed] [Google Scholar]
  • Dantal J, (2013) Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 38: 275–284. doi: 10.1159/000354893 [CrossRef] [PubMed] [Google Scholar]
  • Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP, (1996) Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47: 674–677 [CrossRef] [PubMed] [Google Scholar]
  • Centers for Disease Control and Prevention (CDC), (1999) Renal insufficiency and failure associated with immune globulin intravenous therapy — United States, 1985–1998. MMWR Morb Mortal Wkly Rep 48: 518–521 [PubMed] [Google Scholar]
  • Perazella MA, Cayco AV, (1998) Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise? Am J Ther 5: 399–403 [CrossRef] [PubMed] [Google Scholar]
  • Zhang R, Szerlip HM, (2000) Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J 93: 901–904 [PubMed] [Google Scholar]
  • Khalil M, Shin HJ, Tan A, DuBose TD Jr, Ordóñez N, Katz RL, (2000) Macrophagelike vacuolated renal tubular cells in the urine of a male with osmotic nephrosis associated with intravenous immunoglobulin therapy. A case report. Acta Cytol 44: 86–90 [CrossRef] [Google Scholar]
  • Moreau JF, Noel LH, Droz D, (1993) Proximal renal tubular vacuolization induced by iodinated contrast media, or so-called “osmotic nephrosis.” Invest Radiol 28: 187–190 [CrossRef] [Google Scholar]
  • Legendre C, Thervet E, Page B, Percheron A, Noël LH, Kreis H, (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342: 248–249 [CrossRef] [Google Scholar]
  • Chacko B, John GT, Balakrishnan N, Kirubakaran MG, Jacob CK, (2006) Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 28: 193–195 [CrossRef] [PubMed] [Google Scholar]
  • Chapman SA, Gilkerson KL, Davin TD, Pritzker MR, (2004) Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 38: 2059–2067. doi: 10.1345/aph.1E040 [CrossRef] [PubMed] [Google Scholar]
  • Bollée G, Anglicheau D, Loupy A, Zuber J, Patey N, Mac Gregor D, Martinez F, Mamzer-Bruneel MF, Snanoudj R, Thervet E, Legendre C, Noël LH, (2008) High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 3: 1461–1468. doi: 10.2215/CJN.00500108 [CrossRef] [PubMed] [Google Scholar]
  • Luque Y, Anglicheau D, Rabant M, El Karoui K, Jamme M, Aubert O, Clément R, Noël LH, Bollée G, Brodin-Sartorius A, Martinie M, Kreis H, Timsit MO, Legendre C, (2016) Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. Transpl Int 29: 1205–1215 doi: 10.1111/tri.12833 [CrossRef] [Google Scholar]
  • Levine AA, Levine TD, Clarke K, Saperstein D, (2017) Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders. Muscle Nerve 56: 1173–1176. doi: 10.1002/mus.25693 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.